trial · primary record
Pembrolizumab
Recurrent Anaplastic Large Cell Lymphoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 38 |
| Primary completion | 2026-10-09 |
| Primary endpoint | Evaluate the Safety of Pembrolizumab in Combination With Romidepsin. |
| Registry ID | NCT03278782 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:44:32.051Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03278782
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- PEMBROLIZUMAB · approval
- Pembrolizumab · compound